In Ahern et al. (2018) [64], the authors showed that the combination of PD-1/PD-L1 and CTLA-4 inhibitors in association with RANK-L inhibitors improved the therapeutic response in advanced melanoma patients. This evidence concerns the gene TNFSF11 and melanoma.